Alagille Syndrome Market Research Report – Forecast to 2027

Alagille Syndrome Market Research Report: By Symptom (Liver Problems, Nutrition Problems, Heart Problems, Other), by Treatment (Medications, Kidney Surgery, Other), by Diagnosis (Blood Test, Urinalysis, X-ray Imaging, Other), by End-User-Forecast Till 2027

ID: MRFR/Pharma/4863-HCR | | Region: Global | 100 Pages         

Alagille Syndrome Market Scenario


The alagille syndrome market is expected to grow significantly over the forecast period. Alagille syndrome is a rare genetic condition that can affect the liver and other parts of the body. An individual having alagille syndrome has a fewer number of small bile ducts inside the liver. This causes the bile to build-up inside the liver, which in turn causes liver scarring and damage. Moreover, the signs and symptoms of this syndrome are generally noticed in infancy or early childhood.

The growing occurrence of alagille syndrome, increasing healthcare expenditure, and rising prevalence of genetic diseases are anticipated to drive the growth of the market. According to the US National Library of Medicine, the estimated prevalence of alagille syndrome is 1 in 70,000 newborns.

Despite the drivers, lack of awareness about the syndrome in the developing regions may hamper the growth of the market during the assessment period.

Segmentation

The alagille syndrome global market has been segmented into symptom, treatment, diagnosis, and end-user.

The market on the basis of symptom has been segmented into liver problems, nutrition problems, heart problems, distinctive facial features, neurologic problems, and others.

The market, by treatment, has been segmented into medication, biliary diversion procedures, vitamin supplements, liver transplantation, kidney surgery, heart surgery, and others. The medication segment has been further segmented into Ursodeoxycholic acid, cholestyramine, rifampin, naltrexone, and anti-histamine. The anti-histamine segment has been further segmented into hydroxyzine and others.

The market, by diagnosis, has been segmented into blood test, urinalysis, X-ray imaging, cardiology exam, slit-lamp exam, liver biopsy, genetic testing, prenatal DNA testing, and others.

On the basis of end-user, the market has been segmented into hospitals and clinics, diagnostic centers, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The alagille syndrome market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European alagille syndrome market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The alagille syndrome global market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The alagille syndrome market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


Sanofi AG, Teva Pharmaceutical Industries Ltd., Allergen Plc, Lannett, Albireo Pharma, Inc., AstraZeneca Plc, Novartis AG, Pfizer, Inc., Shire, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Merck & Co., Inc. are some of the key players in the global alagille syndrome market.


Regional Market Summary


Global Alagille Syndrome Market Share (%), by Region, 2017


Alagille Syndrome Market


Source: MRFR Analysis


Geographically, the Americas is anticipated to dominate the global alagille syndrome market owing to a well-developed healthcare sector, rising prevalence of rare genetic disease and growing healthcare expenditure. According to the Global Genes Project, rare and genetic diseases affect 1 in 10 people in the United States Additionally, increasing awareness among the people regarding the disease and well-developed technology is likely to contribute to the growth of the market.


Europe is expected to hold the second largest position in the alagille syndrome global market. The market growth in this region is attributed to the growing prevalence of several liver diseases, increasing prevalence of genetic disease, availability of funds for research, and increasing healthcare expenditure. According to the Public Health England, approximately 11,597 number of people died with an underlying cause of liver disease in England in 2014.  In addition, according to the Office for National Statistics, gross domestic expenditure on research and development (R&D) was Euro 33.1 billion (USD 35.2 billion) in 2016.


Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, growing occurrences of rare diseases and increasing government funding for the healthcare sector.


On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.


Global Alagille Syndrome Market, by Symptom



  • Liver Problems

  • Nutrition Problems

  • Heart Problems

  • Distinctive Facial Features

  • Neurologic Problems

  • Others


Global Alagille Syndrome Market, by Treatment



  • Medications

  • Ursodeoxycholic Acid

  • Cholestyramine

  • Rifampin

  • Naltrexone

  • Anti-histamines

  • Hydroxyzine

  • Others

  • Biliary Diversion Supplements

  • Vitamin supplements

  • Liver Transplantation

  • Kidney Surgery

  • Heart Surgery

  • Others


Global Alagille Syndrome Market, by Diagnosis



  • Blood Test

  • Urinalysis

  • X-ray Imaging

  • Cardiology Exam

  • Slit-lamp Exam

  • Liver Biopsy

  • Genetic Testing

  • Prenatal DNA testing

  • Others


Global Alagille Syndrome Market, by End-User



  • Hospitals and Clinics

  • Diagnostic Centers

  • Others


Global Alagille Syndrome Market, by Region



  • North America


    • US

    • Canada


  • Europe


    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe


  • Asia-Pacific


    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • Rest of the World


    • Middle East

    • Africa

    • Latin America



Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities



Report Scope:

Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2019-2027:Substantial CAGR
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Symptom, Treatment, Diagnosis, And End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Sanofi AG, Teva Pharmaceutical Industries Ltd., Allergen Plc, Lannett, Albireo Pharma, Inc., AstraZeneca Plc, Novartis AG, Pfizer, Inc., Shire, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Merck & Co., Inc
  Key Market Opportunities   Increasing government funding for the healthcare sector
  Key Market Drivers

  • Increasing healthcare expenditure
  • Rising prevalence of genetic diseases


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Alagille market may suffer a setback due to a lack of awareness.

    Symptoms included in the alagille syndrome market are nutrition problems, liver problems, distinctive facial features, neurologic problems, heart problems, and others.

    The segments in alagille syndrome market report are biliary diversion procedures, medication, liver transplantation, vitamin supplements, heart surgery, kidney surgery, and others.

    The segments included in alagille syndrome market report are urinalysis, prenatal DNA testing, blood test, slit-lamp exam, X-ray imaging, cardiology exam, genetic testing, liver biopsy, and others.

    The end users involved in alagille syndrome market report are diagnostic centers, hospitals & clinics, and others.